METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS

Abstract: the human gene scn2a encodes human scn2a protein, the alpha-1 subunit of the voltage-gated sodium channel nav 1.2. mutations in scn2a are associated with a variety of neurodevelopmental and intellectual diseases and disorders, including developmental and epileptic encephalopathy (dee), such as early-onset dee. compositions and methods of using scn2a oligomeric compounds for treating scn2a related disorders, including early onset developmental and epileptic encephalopathy.

Inventor(s): Michael S. Oldham, Steven Petrou

CPC Classification: C12N15/1138 ({against receptors or cell surface proteins})

Search for rejections for patent application number 20250179503